g star 28

g star 28 Alabama flips RB Jace Clarizio from Michigan StateIRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNITM assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-known hallmark of cancer. DetermaCNITM is a patented approach to measuring CNI for the diagnosis and monitoring of cancer. Nearly 300,000 patients in the U.S. each year face primary brain tumors or brain metastasis 1 . The current standard of care for the confirmation and classification of brain tumors often involves high-risk, highly invasive biopsy of brain tissue. Thus, a liquid biopsy method for diagnosing brain tumors could offer significant benefits over currently available methods, representing a potential $300 million U.S. market opportunity. Among the study authors were Oncocyte Chief Science Officer Ekke Schuetz and Senior R&D Director Julia Beck. “This was a proof of principle study to assess whether copy number instability could be measured in the cerebrospinal fluid of patients with brain cancer. The findings suggest that a significant number of the nearly 300,000 patients diagnosed with brain tumors every year in the U.S. could benefit from DetermaCNI,” Dr. Schuetz said. “We congratulate the research team in Frankfurt on the publication of this study in an area of high unmet need.” As noted in the paper, the gold standard for precise diagnostic classification of brain tumors requires a biopsy, with risks including limited sensitivity and failing to measure the diverse potential regions of the tumor. SCNAs were observed in the cerebrospinal fluid of ten out of the 12 patients with confirmed central nervous system cancers. SCNAs were not observed in any of the 11 patients with benign or unclear central nervous system lesions. The detection of SCNAs is highly specific for tumor-derived cell-free DNA (cfDNA). Overall, this new study demonstrates DetermaCNI’s potential for providing a molecularly informed diagnosis of central nervous system cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients through a liquid biopsy of cerebrospinal fluid. Oncocyte believes this study validates the future clinical potential for DetermaCNI, as well as the direction of the company’s research and development pipeline, which is designed to drive sustained rapid growth over the next decade. Oncocyte’s mission is to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. Oncocyte is presently commercializing its transplant product line, which includes the VitaGraftTM and GraftAssureTM tests. It expects to commercialize its oncology assays over the next two years. _______________ 1 “Brain Metastases.” MD Anderson Cancer Center , www.mdanderson.org/cancer-types/brain-metastases.html. And “Brain Tumor Facts.” National Brain Tumor Society , 20 Feb. 2024, braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. About Oncocyte Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based dd-cfDNA solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid dd-cfDNA organ transplantation monitoring test kit for decentralized use. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft Liver TM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 jramson@pcgadvisory.com Forward-Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the belief that the new study validates the future clinical potential for DetermaCNI, as well as the direction of the company’s research and development pipeline, the expectation that Oncocyte will commercialize its oncology assays over the next two years, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Ravens bye week betting notes: AFC North title within reach; Jackson’s MVP odds slip49 Gift Ideas For Anyone Who Still Has A Birthday Before The Year EndsWith over five million units sold globally in the past year, Tineco reinforces its leadership in the industry SEATTLE , Nov. 26, 2024 /PRNewswire/ -- Today, Tineco is proud to announce that Euromonitor International, the world's leading independent provider of strategic market research, has recognized the company as the #1 global leader in the household wet & dry vacuum cleaner category * . With over five million units sold between July 1, 2023 , and June 30, 2024 , the honor reflects Tineco's commitment to innovation and quality in the home cleaning sector. Harnessing more than two decades of industry innovation, Tineco began its journey with a single vacuum cleaner. Pioneering industry excellence, a notable moment in company history was the launch of the first-ever smart vacuum to market in 2018, quickly followed by an inaugural smart floor washer in 2019, and an intelligent carpet cleaner in 2022. Today, Tineco products are enjoyed by 14 million users across key markets worldwide, including regions in North America , Europe , and Asia . Tineco is now a globally recognized market leader in smart home appliances across the floor care, kitchen, and personal care categories, with 975 patents and 577 registered trademarks across domestic and international markets. For three consecutive years, the company has also held the title of being the #1 wet & dry vacuum brand on Amazon in the United States , Canada , France , Italy , Australia , and Japan . "At Tineco's inception, we set out to simplify life and household tasks with the help of smart technology. Over the past 26 years, our robust R&D team has made significant investments and a steadfast dedication to setting the standard for excellence in floor care solutions," said Ling Leng , CEO of Tineco. "The honor of being named the #1 global leader in the wet & dry vacuum cleaner category by Euromonitor International is an incredible milestone achievement. This recognition fuels our commitment to continuing to innovate and push boundaries to bring exceptional products to market that enhance the lives of our customers worldwide. Looking ahead, we are laser-focused on making Tineco more accessible by expanding into new markets, introducing new advanced technologies to simplify our customers' lives, and expanding our product lineup to meet diverse needs." Tineco's flagship models, including FLOOR ONE Stretch S6 , PURE ONE Station 5 , and Carpet One Cruiser , combine intelligent features with superior power and user-friendly capabilities to revolutionize cleaning. Tineco's R&D team has carefully engineered each model to address real-world challenges and enhance user satisfaction by incorporating technological advancements and valuable consumer feedback. Specifically: A leader in the intelligent floor care category, Tineco smart models are equipped with Tineco's proprietary iLoop technology that adjusts suction power in real-time based on the mess detected, which not only optimizes battery power but also allows the user to visualize cleaner floors on the unit's display ring that will change from red to blue once the surface is clean. Guided by customer insights, all new Tineco models also feature self-cleaning capabilities that significantly streamline maintenance. Tineco products are available globally, with distribution in North America on Amazon, Tineco's official online store, and in over 10,000 major retail locations, including Target, Walmart, Best Buy, Costco, Home Depot, and Canadian Tire. To learn more about Tineco and its entire portfolio of intelligent stick vacuums, floor washers, carpet cleaners, and more, please visit us.tineco.com . *Source: Euromonitor International ( Shanghai ) Co., Ltd.; measured in terms of 2023 H2 and 2024 H1 retail sales volume in the world; household wet & dry vacuum cleaners are defined as household cleaners that dispense clean water (or cleaning solution) to wash hard floors and vacuum the dirty water and garbage thereafter; research completed in Nov. 2024 . About Tineco Tineco was founded in 1998 with its first SKU as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has innovated into a global leader offering intelligent appliances across home categories, including floor care, kitchen, and personal care. Tineco is dedicated to its brand vision of making life easier through smart technologies and consistently innovating new devices. For more information, visit us.tineco.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/tineco-recognized-as-global-leader-in-emerging-floor-washer-category-302316066.html SOURCE TINECO

HP earnings in line with expectations, CEO says tariffs would hit the consumerXRAY Investors Have Opportunity to Lead Dentsply Sirona Inc. Securities Fraud Lawsuit

ALTOONA, Pa. — The suspect in the killing of UnitedHealthcare’s CEO struggled with deputies and shouted Tuesday while arriving for a court appearance in Pennsylvania, a day after he was arrested at a McDonald’s and charged with murder. Luigi Nicholas Mangione emerged from a patrol car, spun toward reporters and shouted something partly unintelligible referring to an “insult to the intelligence of the American people” while deputies pushed him inside. Prosecutors began to take steps to bring Mangione back to New York to face a murder charge while new details emerged about his life and how he was captured. The 26-year-old Ivy League graduate from a prominent Maryland real estate family was charged with murder hours after he was arrested in the Manhattan killing of Brian Thompson, who led the United States’ largest medical insurance company. At the brief hearing, defense lawyer Thomas Dickey informed the court that Mangione would not waive extradition to New York but instead wants a hearing on the issue. He has 14 days to challenge detention. Mangione likely was motivated by his anger with what he called “parasitic” health insurance companies and a disdain for corporate greed, a law enforcement bulletin obtained by The Associated Press said. He wrote that the U.S. has the most expensive health care system in the world and that profits of major corporations continue to increase while “our life expectancy” does not, according to the bulletin, based on a review of his hand-written notes and social media posts. Mangione called “Unabomber” Ted Kaczynski a “political revolutionary” and may have found inspiration from the man who carried out a series of bombings while railing against modern society and technology, according to the bulletin. Mangione remained jailed in Pennsylvania, where he was initially charged with possession of an unlicensed firearm, forgery and providing false identification to police. Manhattan prosecutors obtained an arrest warrant, a step that could help expedite his extradition from Pennsylvania. Mangione was arrested Monday in Altoona, Pennsylvania — about 230 miles west of New York City — after a McDonald’s customer recognized him and notified an employee, authorities said. Thompson, 50, was killed Wednesday as he walked alone to a Manhattan hotel for an investor conference. Police saw the shooting as a targeted attack. Get local news delivered to your inbox!

Ryan Talbot | rtalbot@nyup.com The Buffalo Bills’ seven game win streak came to an end at the hands of the Los Angeles Rams. Los Angeles was close to flawless on offense. Matthew Stafford played his best game of the season and his top receivers, Puka Nacua and Cooper Kupp, caught just about everything thrown their way. Kyren Williams was as good as advertised on the ground with two touchdowns while his backup, Blake Corum, averaged 4.3 yards on the ground. The biggest difference in the game, however, was a blocked punt that was returned for a touchdown. Buffalo’s defense and special teams were outcoached and outplayed in Los Angeles. After suffering their third loss of the season, a 44-42 defeat, Buffalo will have to rebound quickly with a matchup against the Detroit Lions looming. Ahead of that matchup, here is a look at where the Bills find themselves on national power rankings as well as analysis from the sites. Most shocking ranking: 19th in time of possession The Bills are second in the NFL in points margin per game (9.9) and have the ninth-most rushes per game (27.8). Despite all of that, winning the time of possession (29:40) battle has not been a strength. Part of that is due to the Bills’ ability to score quickly, as they’re averaging 30.5 points per game. It’s also due to the defense struggling to get off the field -- it’s eighth worst in third-down defense, which was an extreme issue against the Rams. The good: The Khalil Shakir breakout game has arrived. For those of us who have been promising the full realization of his talent for a while now it truly is a great time to say I told you so. I was so impressed by his ability to take an underthrown Josh Allen ball in the fourth quarter from yesterday and turn it into a massive pass interference penalty, showing his veteran chops as well as his breakaway speed on the touchdown. The bad: Taking a quarterback sneak at the end of that game with three timeouts. Sean McDermott has been rightfully held to task for this one. If we’re going to lift him up for making the big call against Kansas City, we are obligated to point out that depriving this team of a chance to hold the Rams on one series and get the ball back was a poor choice, especially since Allen did not have a good look on that sneak. “Josh Allen is an alien.” Quite the assessment from Rams HC Sean McVay, who watched the very legal alien account for six touchdowns Sunday even though the AFC East champs dropped a 44-42 decision. The effort might help Allen land the MVP award, but the loss seriously damaged Buffalo’s bid to win the conference’s No. 1 playoff seed. Josh Allen was Superman. The defense was Clark Kent. Josh Allen’s odds to win MVP got a lot better even in a loss. The Bills’ hopes of avoiding Arrowhead Stadium in January didn’t. Giving up 44 points to the Rams and losing Sunday might define the AFC playoffs. Even Josh Allen and his amazing play couldn’t overcome the bad showing by the defense in the loss to the Rams. Now that defense will be tested again by the explosive Lions this week. The irony of Sunday’s loss in L.A. is that it seems to have boosted Josh Allen’s MVP case, and it’s not hard to see why. Allen was absolutely electric in the 44-42 shootout, accounting for all six Bills touchdowns and nearly bringing the team all the way back from down 17 points in the fourth quarter. Buffalo couldn’t finish the job, but Allen gave the Bills a chance in a game where their defense got just three stops in nine series and couldn’t force a turnover for the first time in a game since last season. It was arguably Buffalo’s worst defensive showing of the season, right up there with the Ravens loss, and it raises some questions about this unit -- even with all the good things it has done -- heading into a possible Super Bowl preview against the 12-1 Lions on Sunday. It was also a tough day on special teams with a blocked punt returned for touchdown. Allen can often overcome a subpar game from the defense, but that extra TD made it a bridge too far. There wasn’t a hotter team in the league entering Week 14 than the Buffalo Bills. In their previous two games, the Bills had defeated both of last year’s Super Bowl participants—including handing the Kansas City Chiefs their only loss of the season. Bills quarterback Josh Allen was amazing against the Rams, throwing three touchdown passes and running for three more. He’s the first player in NFL history to accomplish this feat. But the Bills came up short in one important statistical category. The scoreboard. “Hate losing,” Allen told reporters after the game. “If you lose by two or lose by 100, it doesn’t matter, you are still losing. Offensively, we have to find ways to score before and after the half. We didn’t do our part.” Bills head coach Sean McDermott credited the Rams for flat-out playing better. “They did a great job controlling the line of scrimmage on both sides of the ball,” McDermott said. “Defensively and special teams, neither were good enough to help us win this game.” Analyst’s Take After Sunday’s loss to the Rams, I have some serious concerns about Buffalo’s Super Bowl chances that I didn’t have only a few days ago. As was the case in the early-season loss to the Ravens, the Bills defense largely failed to show up in Week 14. As was the case in the loss to Houston, some questionable clock management hurt Buffalo late. Josh Allen had arguably his most impressive game of the season against a team clawing just to reach the playoffs, and it wasn’t enough. The Bills simply can’t expect to win a Super Bowl as a one-man show. They’re also running out of chances to steal the No. 1 seed, which they might need, as all three of their losses have been on the road. More buffalo bills Bills PFF Week 14 Grades: Tackling dooms Buffalo’s defense vs. Rams Bills coach defends decisions to run Josh Allen, blow timeout vs. Rams on final drive The numbers from Bills-Rams historic offensive game (box score) Josh Allen’s 6 TD effort wiped away by Bills’ embarrassing defensive performance (encouraged/worried) Bills blow historic Josh Allen performance, fall in shootout to Rams (takeaways)